In 643 participants with platinum-resistant recurrent ovarian cancer, adding pembrolizumab to weekly paclitaxel improved PFS at interim analysis (median 8.3 v 6.4 months; HR 0.70) and OS at final analysis (17.7 v 14.0 months; HR 0.82). Grade ≥3 treatment-related AEs 68% v 55%.
RCTn = 643
Colombo et al. Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study